Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22595663 | 0.97 | EGFR (1.00) | EGFR | |
| SCHEMBL22821788 | 0.97 | EGFR (0.95) | EGFR | |
| SCHEMBL22595445 | 0.95 | EGFR (0.93) | EGFR | |
| SCHEMBL26053608 | 0.95 | EGFR (0.90) | EGFR | |
| SCHEMBL22821707 | 0.94 | EGFR (0.89) | EGFR | |
| SCHEMBL22595305 | 0.94 | EGFR (0.89) | EGFR | |
| SCHEMBL22821921 | 0.94 | EGFR (0.88) | EGFR | |
| SCHEMBL25340594 | 0.94 | EGFR (0.88) | EGFR | |
| SCHEMBL22821816 | 0.94 | EGFR (0.88) | EGFR | |
| SCHEMBL30579737 | 0.94 | EGFR (0.88) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022262857-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS | 微境生物医药科技(上海)有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022002100-A1 | NOVEL BENZIMIDAZOLE COMPOUND | 微境生物医药科技(上海)有限公司 | 2022-01-06 | — | — | WO | disclosed |
| WO-2021249324-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2021-12-16 | — | — | WO | disclosed |
| WO-2021160087-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2020253862-A1 | NITROGEN-CONTAINING ARYL PHOSPHORUS OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020200191-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-10-08 | — | — | WO | disclosed |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | EGFR 1/4885 |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | EGFR 1/4885 |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | EGFR 2/4885 |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | EGFR, ERBB2, ERBB3 | EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.